Organogenesis (NASDAQ:ORGO) Stock Price Down 3.8% - Here's Why

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) shares traded down 3.8% on Monday . The company traded as low as $4.15 and last traded at $4.10. 158,757 shares were traded during mid-day trading, a decline of 86% from the average session volume of 1,110,966 shares. The stock had previously closed at $4.26.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley increased their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Price Performance

The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average of $4.39 and a two-hundred day moving average of $3.72. The company has a market capitalization of $535.21 million, a PE ratio of -70.33 and a beta of 1.79.

Insider Buying and Selling at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the transaction, the director now directly owns 166,879 shares of the company's stock, valued at approximately $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 36.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock worth $187,000 after acquiring an additional 4,239 shares during the period. Millennium Management LLC raised its holdings in Organogenesis by 2.8% in the fourth quarter. Millennium Management LLC now owns 208,420 shares of the company's stock worth $667,000 after purchasing an additional 5,765 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock worth $65,000 after acquiring an additional 6,689 shares in the last quarter. Rhumbline Advisers grew its holdings in Organogenesis by 7.1% in the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock worth $369,000 after purchasing an additional 7,621 shares during the period. Finally, State Street Corp increased its stake in shares of Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company's stock valued at $4,175,000 after purchasing an additional 9,090 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.